var data={"title":"Ibritumomab tiuxetan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibritumomab tiuxetan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibritumomab-tiuxetan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibritumomab tiuxetan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708911\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infusion reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ibritumomab tiuxetan therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. Discontinue rituximab and Y-90 ibritumomab tiuxetan infusions in patients who develop severe infusion reactions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Prolonged and severe cytopenias:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Y-90 ibritumomab tiuxetan administration results in severe and prolonged cytopenias in most patients. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with 25% or greater lymphoma marrow involvement and/or impaired bone marrow reserve.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe cutaneous and mucocutaneous reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the ibritumomab tiuxetan therapeutic regimen. Discontinue rituximab and Y-90 ibritumomab tiuxetan infusions in patients experiencing severe cutaneous or mucocutaneous reactions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dosing:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The dose of Y-90 ibritumomab tiuxetan should not exceed 32 mCi (1,184 MBq).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181392\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zevalin Y-90</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663220\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zevalin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181405\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD20;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody;</li>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181395\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with oral acetaminophen 650 mg and oral diphenhydramine 50 mg prior to <b>each</b> rituximab infusion. Allow at least 6 weeks, but no more than 12 weeks following first-line chemotherapy before treatment initiation; platelets should recover to &ge;150,000/mm<sup>3</sup> prior to initiation of treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphoma:</b> Ibritumomab is administered <b>only</b> as part of the Zevalin therapeutic regimen (a combined treatment regimen with rituximab). The regimen consists of two steps:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Day 1:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rituximab:</i> IV: 250 mg/m<sup>2</sup> at an initial rate of 50 mg/hour. If hypersensitivity or infusion-related events do not occur, increase infusion in increments of 50 mg/hour every 30 minutes, to a maximum of 400 mg/hour. Stop rituximab and discontinue regimen for severe infusion reaction. For less severe infusion reactions, temporarily slow or interrupt; the infusion may be resumed at one-half the previous rate upon improvement of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Day 7, 8, or 9 of treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rituximab:</i> IV: 250 mg/m<sup>2</sup> at an initial rate of 100 mg/hour (50 mg/hour if infusion-related events occurred with the day 1 infusion). If hypersensitivity or infusion-related events do not occur, increase infusion in increments of 100 mg/hour every 30 minutes, to a maximum of 400 mg/hour, as tolerated (increase in 50 mg/hour increments every 30 minutes if initial infusion rate was 50 mg/hour).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Y-90 ibritumomab (within 4 hours after completion of the rituximab infusion):</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &ge;150,000 cells/mm<sup>3</sup>: 0.4 mCi/kg (14.8 MBq/kg) actual body weight over 10 minutes; maximum dose: 32 mCi (1184 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count between 100,000 to 149,000 cells/mm<sup>3</sup> (in relapsed or refractory patients): 0.3 mCi/kg (11.1 MBq/kg) actual body weight over 10 minutes; maximum dose: 32 mCi (1184 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;100,000 cells/mm<sup>3</sup>: Do <b>not</b> administer</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Maximum dose:</b> The prescribed, measured, and administered dose of Y-90 ibritumomab must not exceed 32 mCi (1184 MBq), regardless of the patient's body weight</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062779\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897585\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897586\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181371\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zevalin Y-90: 3.2 mg/2 mL [pyrogen free; contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181359\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181373\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rituximab: Administer the first infusion of rituximab at an initial rate of 50 mg/hour. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hour increments every 30 minutes, to a maximum of 400 mg/hour. Immediately stop infusion for severe infusion reaction (discontinue ibritumomab regimen); less severe reactions may be managed by slowing or interrupting infusion. For less severe reactions, infusion may continue at one-half the previous rate upon improvement of patient symptoms. If infusion reaction did not occur in initial rituximab infusion, subsequent rituximab infusion can be administered at an initial rate of 100 mg/hour and increased in 100 mg/hour increments at 30-minute intervals, to a maximum of 400 mg/hour as tolerated. If infusion reaction occurred with initial rituximab infusion, initiate at 50 mg/hour with increases of 50 mg/hour increments every 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Y-90 ibritumomab: Begin within 4 hours of completion of rituximab infusion. Inject slowly, over 10 minutes through a 0.22 micron low protein binding in-line filter (filter placed between syringe and infusion port) into a free-flowing IV line. After injection, flush line with at least 10 mL normal saline. Avoid extravasation; closely monitor infusion site; if signs or symptoms of extravasation occur, stop infusion and restart in another limb. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181372\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Non-Hodgkin lymphoma:</b> Treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL); treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401646\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ibritumomab tiuxetan may be confused with inotuzumab ozogamicin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181364\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (18%), abdominal pain (17%), diarrhea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocytopenia (62% to 95%; grades 3/4: 51% to 63%; nadir: 49-53 days; median duration: 24 days; median time to recovery: 13 days), neutropenia (45% to 77%; grades 3/4: 41% to 60%; nadir: 61-62 days; median duration: 22 days; median time to recovery: 12 days), anemia (22% to 61%; grades 3/4: 5% to 17%; nadir: 68-69 days), leukopenia (43%; grades 3/4: 36%), lymphocytopenia (26%; grades 3/4: 18%), metastases (1% to 13%; includes acute myelogenous leukemia and myelodysplastic syndrome)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (within first 3 months: 29%; serious: 1% to 3%; 3 months to 4 years after treatment: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (19%), cough (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Night sweats (8%), pruritus (7%), skin rash (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Anorexia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Petechia (8%), bruise (7%), severe cytopenia (prolonged: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Antibody development (HAMA/HACA: 1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchitis (8%), flu-like symptoms (8%), rhinitis (8%), pharyngolaryngeal pain (7%), sinusitis (7%), epistaxis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (10%), biodistribution altered (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Adult respiratory distress syndrome, angioedema, bullous dermatitis, cardiogenic shock, chills, dyspnea, erythema multiforme, exfoliative dermatitis, febrile neutropenia, headache, hypoxia, infusion-related reaction, injection site reaction (erythema/ulceration following extravasation), myocardial infarction, pain, pulmonary infiltrates, radiation injury (delayed [~1 month]; in tissues in or near areas of lymphomatous involvement), sepsis, Stevens-Johnson syndrome, tissue necrosis (following Yttrium-90-ibritumomab extravasation), toxic epidermal necrolysis, ventricular fibrillation, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181376\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181362\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Delayed, prolonged, and severe cytopenias (thrombocytopenia and neutropenia) are common. Do not administer to patients with &ge;25% lymphoma marrow involvement, patients with impaired bone marrow reserve </b>(eg, prior myeloablative treatment, platelet count &lt;100,000/mm<sup>3</sup>, neutrophil count &lt;1,500/mm<sup>3</sup>, hypocellular marrow), or to patients with prior stem cell collection failure. In studies, the median platelet, ANC, and hemoglobin nadir was 49 to 53 days, 61 to 62 days, and 68 to 69 days, respectively. Cytopenias may persist beyond 12 weeks. The median duration of thrombocytopenia and neutropenia was 24 to 35 days and 22 to 29 days respectively, and the median time to platelet and ANC recovery was 13 to 14 days and 12 to 15 days, respectively. Patients with mild baseline thrombocytopenia (100,000 to 149,000/mm<sup>3</sup>) may experience higher incidences of severe neutropenia and thrombocytopenia. Hemorrhage may occur due to thrombocytopenia; avoid concomitant use of medications interfering with coagulation or platelet function. Monitor CBC and platelets weekly until recovery or as clinically indicated. Closely monitor patients for complications of cytopenias (eg, febrile neutropenia, hemorrhage) for up to 3 months after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous/mucocutaneous reactions: <b>[US Boxed Warning]: Severe cutaneous and mucocutaneous skin reactions have been reported (with fatalities). Discontinue all components of the therapeutic regimen in patients experiencing severe cutaneous or mucocutaneous skin reactions,</b> including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, and exfoliative dermatitis. Onset may occur within days to 4 months following infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation/radiation necrosis: Infusion site erythema and ulceration have been reported following extravasation; monitor infusion site; promptly terminate infusion with symptoms/signs of extravasation (restart in another limb). There is a case report of (delayed) erythema and ulceration, which is described as radiation necrosis following yttrium-90-ibritumomab extravasation (Williams 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: <b>[US Boxed Warning]: Serious fatal infusion reactions may occur with the rituximab component of the therapeutic regimen. Immediately stop infusion and discontinue all components of the therapeutic regimen in patients who develop severe infusion reactions. Fatalities due to rituximab infusion were associated with acute respiratory distress syndrome, hypoxia, pulmonary infiltrates, cardiogenic shock, MI, or ventricular fibrillation; 80% of fatalities occurred with the first rituximab infusion.</b> Administer in a facility with immediate access to resuscitative measures. Infusion reactions typically occur with the first rituximab infusion (onset within 30 to 120 minutes). Other reactions may include hypotension, angioedema, bronchospasm, and urticaria. Less severe reactions may be managed by slowing or temporarily interrupting infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation injury: Delayed (up to 1 month) radiation injury has occurred in or near areas of lymphomatous involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Malignancies due to the radiation dose from therapeutic exposure may occur. Secondary malignancies (acute myelogenous leukemia and/or myelodysplastic syndrome) have been reported; the median time to secondary malignancy diagnosis following ibritumomab treatment was 1.9 years with a range of 0.4 to 6.3 years (Czuczman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product contains albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. The contents of the kit are not radioactive until radiolabeling occurs. During and after radiolabeling, adequate shielding should be used with this product, minimize radiation exposure (to patient and health care professionals) in accordance with institutional radiation safety practices.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biodistribution: In a postmarketing registry of biodistribution images, biodistribution was altered in a limited number of patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced professionals: Use should be reserved to physicians and other professionals qualified and experienced in the safe handling of radiopharmaceuticals, and in monitoring and emergency treatment of infusion reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B screening: American Society of Clinical Oncology (ASCO) provisional clinical opinion update on hepatitis B virus screening recommendations (Hwang 2015): Patients receiving anti-CD20 antibodies are at high risk for hepatitis B virus (HBV) reactivation. Screen for HBV infection with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). In addition, patients who have risk factors for HBV infection (eg, birthplace in a country with &ge;2% HBV prevalence, household or sexual contact with HBV infected patients, high-risk behaviors [eg, IV drug use], and HIV infection) should also be screened prior to beginning therapy. Initiate prophylactic antiviral therapy (utilizing antivirals with low rates of viral resistance) for HBsAg positive/anti-HBc positive patients (without delaying cancer therapy) and continue the antivirals during and for ~6 to 12 months after completing treatment. HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment; antiviral therapy may be initiated prophylactically or begun promptly at the first sign of HBV reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Do not administer live viral vaccines to patients who have recently received ibritumomab treatment. The safety of immunization with live vaccines following ibritumomab therapy has not been studied; the ability to generate a response to any vaccine after receiving treatment has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maximum dose:<b> [US Boxed Warning]: Do not exceed the Y-90 ibritumomab maximum allowable dose of 32 mCi (1184 MBq).</b> To be used as part of the Zevalin therapeutic regimen (in combination with rituximab).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299501\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181366\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8709&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181368\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181378\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Based on the radioactivity, Y-90 ibritumomab may cause fetal harm if administered during pregnancy. IgG molecules are known to cross the placenta. Women of reproductive potential should avoid becoming pregnant during treatment with ibritumomab. Females of reproductive potential and males with female partners of reproductive potential should use effective contraception for at least 12 months following treatment. The effect on future fertility is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181379\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known whether ibritumomab is present in breast milk. Because many immunoglobulins are excreted in milk and due to the potential for serious adverse reactions in the breastfeeding infant, a decision should be made to either discontinue breastfeeding or to not administer ibritumomab, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181369\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CBC with differential and platelet counts weekly until recovery, or as clinically indicated. Platelet count must be obtained prior to day 7, 8, or 9; monitor for cytopenias (and related complications) for up to 3 months after use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatitis B virus screening recommendations (ASCO provisional clinical opinion update [Hwang 2015]): Screen for hepatitis B virus (HBV) infection with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for signs of active hepatitis B infection (during and for up to 12 months after therapy completion). Monitor for infusion-related allergic reactions (typically within 30 to 120 minutes of administration), for extravasation during ibritumomab infusion; and for severe cutaneous and mucocutaneous reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181361\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ibritumomab is a monoclonal antibody directed against the CD20 antigen found on pre-B and mature B lymphocytes (normal and malignant). Ibritumomab binding induces apoptosis in B lymphocytes <i>in vitro</i>. It is combined with the chelator tiuxetan, which acts as a specific chelation site for Yttrium-90 (Y-90). The monoclonal antibody acts as a delivery system to direct the radioactive isotope to the targeted cells, however, binding has been observed in lymphoid cells throughout the body and in lymphoid nodules in organs such as the large and small intestines. Beta-emission induces cellular damage through the formation of free radicals (in both target cells and surrounding cells).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181375\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: B cell recovery begins in ~12 weeks; generally in normal range within 9 months </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: To lymphoid cells throughout the body and in lymphoid nodules in organs such as the large and small intestines, spleen, testes, and liver </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Has not been characterized; the product of yttrium-90 radioactive decay is zirconium-90 (nonradioactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Y-90 ibritumomab: 30 hours; Yttrium-90 decays with a physical half-life of 64 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: A median of 7.2% of the radiolabeled activity was excreted in urine over 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323189\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Zevalin Y-90 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.2 mg/2 mL (1): $56,648.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539878\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Zevalin (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IT, KR, LT, LU, LV, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TH, TR);</li>\n      <li>Zevamab (AR, CO, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cheson BD, &ldquo;Radioimmunotherapy of Non-Hodgkin Lymphomas,&rdquo; <i>Blood</i>, 2003, 101(2):391-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12393555/pubmed\" target=\"_blank\" id=\"12393555\">12393555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czuczman MS, Emmanouilides C, Darif M, et al, &ldquo;Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy,&rdquo; <i>J Clin Oncol</i>, 2007, 25(27):4285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/17709799/pubmed\" target=\"_blank\" id=\"17709799\">17709799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordon LI, Molina A, Witzig T, et al, &ldquo;Durable Responses after Ibritumomab Tiuxetan Radioimmunotherapy for CD20+ B-Cell Lymphoma: Long-Term Follow-Up of a Phase 1/2 Study,&rdquo; <i>Blood</i>, 2004, 103(12):4429-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/15016644/pubmed\" target=\"_blank\" id=\"15016644\">15016644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. <i>J Clin Oncol</i>. 2015;33(19):2212-2220. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/25964247/pubmed\" target=\"_blank\" id=\"25964247\">25964247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90-yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i>. 2012;119(26):6373-6378. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/22586182/pubmed\" target=\"_blank\" id=\"22586182\">22586182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morschhauser F, Radford J, Van Hoof A, et al, &ldquo;Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2008, 26(32):5156-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/18854568/pubmed\" target=\"_blank\" id=\"18854568\">18854568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morschhauser F, Radford J, Van Hoof A, et al. 90-Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. <i>J Clin Oncol</i>. 2013;31(16):1977-1983.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/23547079/pubmed\" target=\"_blank\" id=\"23547079\">23547079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams G, Palmer MR, Parker JA, et al, &ldquo;Extravasation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin&reg;): A Case Report,&rdquo; <i>Cancer Biother Radiopharm</i>, 2006, 21(2):101-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/16706630/pubmed\" target=\"_blank\" id=\"16706630\">16706630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witzig TE, Gordon LI, Cabanillas F, et al, &ldquo;Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2002, 20(10):2453-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12011122/pubmed\" target=\"_blank\" id=\"12011122\">12011122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witzig TE, White CA, Gordon LI, et al, &ldquo;Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin&rsquo;s Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2003, 21(7):1263-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12663713/pubmed\" target=\"_blank\" id=\"12663713\">12663713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witzig TE, White CA, Wiseman GA, et al, &ldquo;Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20(+) B-Cell Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 1999, 17(12):3793-803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/10577851/pubmed\" target=\"_blank\" id=\"10577851\">10577851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zevalin (ibritumomab) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals;August 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8709 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708911\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181392\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663220\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181405\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181395\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062779\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897585\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897586\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181371\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181359\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181373\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181372\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401646\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181364\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181376\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181362\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299501\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181366\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F181368\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181378\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F181379\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181369\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181361\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181375\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323189\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539878\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8709|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibritumomab-tiuxetan-patient-drug-information\" class=\"drug drug_patient\">Ibritumomab tiuxetan: Patient drug information</a></li></ul></div></div>","javascript":null}